Edition:
United Kingdom

People: Biohaven Pharmaceutical Holding Company Ltd (BHVN.N)

BHVN.N on New York Stock Exchange

61.70USD
20 May 2019
Change (% chg)

$-0.11 (-0.18%)
Prev Close
$61.81
Open
$60.81
Day's High
$63.24
Day's Low
$60.81
Volume
115,200
Avg. Vol
133,148
52-wk High
$65.55
52-wk Low
$29.17

Conway, Charles 

Dr. Charles Conway, Ph.D. serves as Chief Scientific Officer of the Company. From January 2000 to January 2017, he held positions of increasing responsibility in drug discovery at BMS, most recently serving as associate director—biology analytics. Dr. Conway led BMS's biology program efforts working on the CGRP antagonist program for over 10 years and was part of the full development team advancing rimegepant into the clinic. Dr. Conway has extensive experience in the field of pain research and is an inventor on three granted U.S. patents for the treatment of pain. Prior to his time at BMS, Dr. Conway was a postgraduate research anesthesiologist at the University of California San Diego. Dr. Conway received his B.S. in experimental psychology from the University of Central Missouri and his Ph.D. in neuroscience from the University of California Santa Barbara.

Basic Compensation

Total Annual Compensation, USD 1,616,220
Restricted Stock Award, USD --
Long-Term Incentive Plans, USD --
All Other, USD 9,932
Fiscal Year Total, USD 1,626,150

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --
Name Fiscal Year Total

Declan Doogan

247,770

Vlad Coric

3,855,660

James Engelhart

2,510,280

Charles Conway

1,626,150

Kimberly Gentile

--

Robert Berman

521,060
As Of  31 Dec 2017